By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Aptalis Pharma US Inc. et al.
v. Mylan Pharamaceuticals, Inc. et al.
3:13-cv-04158; filed July 5,
2013 in the District Court of New Jersey

• Plaintiffs:  Aptalis Pharma US
Inc.; Aptalis Pharma Canada Inc.
• Defendants:  Mylan
Pharamaceuticals, Inc.; Mylan Inc.

Infringement of U.S. Patent
Nos. 8,217,083 ("Mesalamine
Suppository," issued July 10,
2012) and 8,436,051 (same title, issued May 7, 2013) following a Paragraph IV
certification as part of Mylan's filing of an ANDA to manufacture a generic
version of Aptalis' Canasa® (mesalamine rectal suppository product, used to
treat active ulcerative proctitis).  View
the complaint here.

Novartis AG et al. v. Accord
Healthcare, Inc. USA et al.
1:13-cv-01013; filed July 3,
2013 in the District Court of the District of Columbia

• Plaintiffs:  Novartis AG;
Novartis Pharmaceuticals Corp.
• Defendants:  Accord
Healthcare, Inc. USA; Intas Pharmaceutical Ltd.

Infringement of U.S. Patent
Nos. 6,025,391 ("Enteric-Coated Pharmaceutical Compositions of
Mycophenolate," issued February 15, 2000), 6,172,107 ("Entric-Coated
Pharmaceutical Compositions," issued January 9, 2001), and 6,306,900 (same
title, issued October 23, 2001) following a Paragraph IV certification as part
of Accord's filing of an ANDA to manufacture a generic version of Novartis'
Myfortic® (mycophenolate sodium, used for the prophylaxis or prevention of
organ rejection in patients receiving allogeneic renal transplants,
administered in combination with cyclosporine and corticosteroids).  View the complaint here.

Purdue Pharma L.P. et al. v.
Teva Pharmaceuticals USA, Inc.
1:13-cv-04606; filed July 2,
2013 in the Southern District of New York

• Plaintiffs:  Purdue Pharma
L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Grunenthal GmbH
• Defendant:  Teva
Pharmaceuticals USA, Inc.

Infringement of U.S. Patent
Nos. 8,337,888 ("Pharmaceutical Formulation Containing Gelling Agent,"
issued December 25, 2012) and 8,309,060 ("Abuse-Proofed Dosage Form,"
issued November 13, 2012) following a Paragraph IV certification as part of
Teva's filing of an ANDA to manufacture a generic version of Purdue Pharma's
OxyContin® (controlled release oxycodone hydrochloride, used to treat
pain).  View the complaint here.

Alpex Pharma, S.A. et al. v.
Zydus Pharmaceuticals USA, Inc. et al.
1:13-cv-04076; filed July 1,
2013 in the District Court of New Jersey

• Plaintiffs:  Alpex Pharma,
S.A.; Citius Pharmaceuticals, LLC.; Prenzamax, LLC
• Defendants:  Zydus
Pharmaceuticals USA, Inc.; Cadila Healthcare Ltd.

Infringement of U.S. Patent
No. 6,149,938 ("Process for the Preparation of a Granulate Suitable to the
Preparation of Rapidly Disintegrable Mouth-Soluble Tablets and Compositions
Obtained Thereby," issued November 21, 2000) following a Paragraph IV
certification as part of Zydus' filing of an ANDA to manufacture a generic
version of Alpex's Suprenza® (phentermine hydrochloride, used to treat
obesity).  View the complaint here.

Trivitis, Inc. v. Primus
Pharmaceuticals, Inc.
3:13-cv-00352; filed July 1,
2013 in the District Court of Nevada

Infringement of U.S. Patent
No. 6,562,864 ("Catechin Multimers as Therapeutic Drug Delivery Agents,"
issued May 13, 2003) based on Primus' manufacture and sale of its Limbrel
product (flavocoxid and citrated zinc bisglycinate, used for the clinical
dietary management of the metabolic processes of osteoarthritis).  View the complaint here.